The agreement will provide the Rochester-based global eye health company with manufacturing capabilities in India to accelerate the launch of new prescription and over-the-counter ophthalmic drops including Moxisurge, Aquasurge, Aquasurge Max, Bromvue, Ketovue and Moxisurge-KT.
Bausch + Lomb will also set up sales and marketing teams, and deliver practitioner and patient education programs in relation to eye care.
As part of the agreement, Bausch + Lomb will source ophthalmic solution products from Micro Labs and, market and sell them in Asia Pacific.
The companies will partner over manufacturing technology for the production of eye drops.
They will also conduct ophthalmic pharmaceutical products research and development for emerging markets.